Breaking: Sofwave Medical Unveils Q1 Fiscal 2025 Performance — Investors Take Note
Sofwave Medical Achieves Impressive Q1 2025 Financial Performance
Sofwave Medical Ltd (TASE: SOFW), a pioneering innovator in non-invasive aesthetic medical devices, has announced robust financial results for the first quarter of fiscal year 2025, demonstrating strong growth and market momentum.
Key Financial Highlights:
- Total revenue reached $16.7 million, representing a remarkable 26% year-over-year increase
- IFRS gross margin stood at an impressive 76.3%, underscoring the company's operational efficiency
- Recurring revenue from pulse segments surged to $7.0 million, a substantial 49% year-over-year growth
- Operating losses remained controlled, with IFRS and non-IFRS operating losses at $1.0 million and $0.2 million respectively
The company continues to solidify its position as a leader in energy-based aesthetic medical technologies, showcasing strong financial performance and strategic growth in the global market.
Issued from San Clemente, California on May 06, 2025